Re: AZD5004 /AZN’s obesity pipeline See slides 23-24 from today’s Investor Day for monotherapy and combination trials. https://www.astrazeneca.com/content/dam/az/Investor_Relations/events/ID/BioPharmaceuticals-presentation.pdf Note: ECC5004 is now called AZD5004.